HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Aclaris Therapeutics, Inc. operates as a clinical-stage specialty pharmaceutical company. The Company focuses on identifying, developing, and commercializing topical drugs to address significant unmet needs in dermatology. Aclaris Therapeutics offers a topical therapy for the treatment of seborrheic keratosis and other verrucoid lesions of the skin.
Market Cap | 909.889 Million | Shares Outstanding | 42.919 Million | Avg 30-day Volume | 1.078 Million | ||
P/E Ratio | -16.12249 | Dividend Yield | 0.0 | EPS | -1.34 | ||
Price/Sales | -376.48 | Debt to Equity | 1.76 | EBITDA | -38.364 Million | ||
Price to Book Value | 25.49 | Forward PE | Enterprise Value | 996.212 Million | |||
Total Cash | 53.477 Million | Current Debt | 12.788 Million | Gross Profit | -4.356 Million | ||
BETA | 0.91013 | 52-week High/Low | 25.48 / 0.7 | Price to Cash FLow (P/CF) | -9999999.0 | ||
Data provided by IEX Cloud |
Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|---|---|---|---|---|---|
In top 10: | 3 | 1 | 200.0% | 2 (0.12%) | 0 (0.0%) | |
Funds Holding: | 81 | 58 | 39.66% | 39 (2.35%) | 25 (1.56%) | 56.0% |
13F shares: | 31.91 Million | 25.554 Million | 24.87% | 24.715 Million | 21.215 Million | 16.5% |
% Ownership | 74.3487 | 59.5405 | 24.87% | 57.586 | 49.4289 | 16.5% |
New Positions: | 30 | 5 | 500.0% | 17 | 3 | 466.67% |
Increased Positions | 15 | 12 | 25.0% | 7 | 7 | 0.0% |
Closed Positions | 7 | 10 | -30.0% | 3 | 4 | -25.0% |
Reduced Positions | 22 | 22 | 0.0% | 12 | 9 | 33.33% |
Total Calls | 472.525 Thousand | 26.6 Thousand | 1676.41% | 450.9 Thousand | 14.3 Thousand | 3053.15% |
Total Puts | 37.105 Thousand | 506 | 7233.0% | 14.3 Thousand | ||
PUT/CALL Ratio | 0.08 | 0.02 | 300.0% | 0.03 | 0.0 | |
1 hedge funds and active managers as identified by whalewisdom.com through public filings. |
Please sign in first
none
none
33.2 Thousand total shares from 5 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FORESITE CAPITAL MANAGEMENT III, LLC FORESITE CAPITAL FUND III, L.P. FORESITE CAPITAL MANAGEMENT IV, LLC FORESITE CAPITAL FUND IV, L.P. |
|
6,612,181 | 2021-02-05 | 1 |
|
30,841 | 2021-02-02 | 3 | |
ALI-JACKSON KAMIL CHIEF LEGAL OFFICER |
|
126,646 | 2021-02-01 | 4 |
RUFFO FRANK CHIEF FINANCIAL OFFICER |
|
215,189 | 2021-02-01 | 4 |
WALKER NEAL PRESIDENT AND CEO |
|
1,155,798 | 2021-02-01 | 5 |
GORDON DAVID N. CHIEF MEDICAL OFFICER |
|
87,535 | 2020-07-02 | 3 |
|
23,891 | 2020-06-04 | 2 | |
|
16,209 | 2020-06-04 | 2 | |
|
16,709 | 2020-06-04 | 2 | |
|
650,664 | 2020-06-04 | 2 | |
|
16,209 | 2020-06-04 | 2 | |
|
0 | 2020-06-04 | 2 | |
|
0 | 2020-06-04 | 1 | |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) |
|
4,123,266 | 2019-06-27 | 0 |
SHANLER STUART CHIEF SCIENTIFIC OFFICER |
|
0 | 2019-03-01 | 0 |
POWALA CHRISTOPHER CHIEF REG & DEVELOP OFFICER |
|
272,163 | 2019-02-01 | 0 |
FAIR BRETT CHIEF COMMERCIAL OFFICER |
|
10,582 | 2019-02-01 | 0 |
|
571,471 | 2018-10-04 | 0 | |
|
No longer subject to file | 2017-08-21 | 0 | |
|
0 | 2017-06-15 | 0 | |
|
8,925,707 | 2017-02-28 | 0 | |
|
No longer subject to file | 2016-09-15 | 0 | |
|
0 | 2016-06-29 | 0 | |
|
2,314,942 | 2015-10-19 | 0 | |
SOFINNOVA VENTURE PARTNERS VIII, L.P. |
|
2,289,480 | 2015-10-13 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-02-03 17:33:10 -0500 | 2021-02-02 | M | 8,000 | d | 0 | direct | ||||||||||
2021-02-03 17:33:10 -0500 | 2021-02-02 | M | 6,632 | $18.32 | a | 30,841 | direct | |||||||||
2021-02-03 17:33:10 -0500 | 2021-02-02 | M | 6,632 | d | 0 | direct | ||||||||||
2021-02-03 17:33:10 -0500 | 2021-02-02 | M | 8,000 | $18.35 | a | 24,209 | direct | |||||||||
2021-02-03 17:23:56 -0500 | 2021-02-01 | M | 10,800 | a | 1,159,114 | direct | ||||||||||
2021-02-03 17:29:24 -0500 | 2021-02-01 | M | 3,875 | d | 3,875 | direct | ||||||||||
2021-02-03 17:26:46 -0500 | 2021-02-01 | M | 3,875 | d | 3,875 | direct | ||||||||||
2021-02-03 17:23:56 -0500 | 2021-02-01 | M | 10,800 | d | 10,800 | direct | ||||||||||
2021-02-03 17:29:24 -0500 | 2021-02-01 | F | 1,308 | $21.35 | d | 215,189 | direct | |||||||||
2021-02-03 17:26:46 -0500 | 2021-02-01 | F | 1,318 | $21.35 | d | 126,646 | direct | |||||||||
2021-02-03 17:23:56 -0500 | 2021-02-01 | F | 3,316 | $21.35 | d | 1,155,798 | direct | |||||||||
2021-02-03 17:29:24 -0500 | 2021-02-01 | M | 3,875 | a | 216,497 | direct | ||||||||||
2021-02-03 17:26:46 -0500 | 2021-02-01 | M | 3,875 | a | 127,964 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 22:15:02 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 21:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 21:15:02 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 20:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 20:15:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 19:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 19:15:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 18:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 18:15:02 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 17:45:02 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 17:15:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 16:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 16:15:02 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 15:45:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 15:15:03 UTC | -1.5065 | 1.5765 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 14:45:03 UTC | -0.6129 | 0.6829 | 450000 |
ACLARIS THERAPEUTICS INC ACRS | 2021-02-26 13:00:03 UTC | -0.6129 | 0.6829 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|